NeoTYPE® Cervical Tumor Profile
Also known as: Cervical Tumor Profile
Use
The NeoTYPE Cervical Tumor Profile provides comprehensive genomic profiling of cervical tumors through the analysis of 43 biomarkers using next-generation sequencing (NGS), FISH, and IHC. This test aids in treatment decision-making by providing a summary interpretation of results. Reflex testing is available in specific scenarios to refine results further, such as reflexing to the NTRK NGS Fusion Panel or MSI by PCR depending on the biomarker expressions and tumor characteristics.
Special Instructions
Results are provided with a summary interpretation to assist with clinical decisions. If Pan-TRK IHC is expressed or equivocal, reflex testing will be performed. Ensure FFPE tissue is prepared using 10% buffered formalin fixative and transported on a cold pack.
Limitations
The test may not detect all types of mutations or biomarkers outside of the specifically listed genes and proteins. MSI NGS result may require reflex to MSI by PCR if indeterminate. The performance of the test can be influenced by sample quality and the percentage of tumor in the sample.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Paraffin block
Collection Instructions
Use 10% buffered formalin fixative. Do not use zinc fixatives.
Storage Instructions
Use cold pack for transport, ensuring the cold pack is not in direct contact with the specimen. NYS clients please provide date and time of collection.